Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration int
Large national cohort study with 34,427 consecutive CLL diagnoses, multivariable analysis adjusting for key confounders, and hard clinical endpoints (overall and cause-specific survival) demonstrating previously unreported socioeconomic and geographic disparities.